Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,565 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Enrolling by invitation Phase 2 Interventional

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

NCT06275620
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
AGTC-501 (high dose and standard corticosteroid regimen), AGTC-501 (low dose and standard corticosteroid regimen), AGTC-501 (high dose and modified corticosteroid regimen)
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
12 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
7
States / cities
Jacksonville, Florida • Miami, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

NCT04519658
View directory record Official record
Conditions
Resistant Hypertension
Interventions
CIN-107, Placebo
Drug
Lead sponsor
CinCor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
80
States / cities
Birmingham, Alabama • Saraland, Alabama • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

NCT02024555
View directory record Official record
Conditions
Sarcoidosis; Antimycobacterial Therapy
Interventions
Levofloxacin, Ethambutol, Azithromycin, Rifampin, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Albany, New York • Cincinnati, Ohio • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Fasting-Mimicking Diet on Skin Health

NCT05564624
View directory record Official record
Conditions
Skin
Interventions
Fasting mimicking diet (FMD)
Other
Lead sponsor
L-Nutra Inc
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

NCT03304379
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Diclofenac, Celecoxib, Matching placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
71
States / cities
Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

NCT01939496
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
54
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Not applicable Interventional Results available

Fully Remote Use of IpsiHand Device in Hemiparetic Stroke

NCT05965713
View directory record Official record
Conditions
Stroke, Hemiparesis, Spasticity as Sequela of Stroke, Brain Computer Interface, Chronic Stroke Survivors With Plegic Hand
Interventions
Neurolutions IpsiHand Upper Extremity Rehabilitation System, Home Exercise rehabilitation regimen Program (HEP)
Device · Other
Lead sponsor
Neurolutions, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Not applicable Interventional

The Use of Serratus Block for Cardiac Surgery

NCT03237546
View directory record Official record
Conditions
Cardiac Surgery
Interventions
Anesthetic regimen including SB, Anesthetic regimen including SB or no block
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility and Efficacy of A Remote Tai Chi Program in Older Adults

NCT06918678
View directory record Official record
Conditions
Aging
Interventions
Tai Chi intervention, Usual care condiition
Device · Other
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
60 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone

NCT00763815
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Pioglitazone, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 30, 2026, 6:19 AM EDT
Completed No phase listed Observational

The Von Willebrand Disease (VWD) International Prophylaxis Study

NCT00557908
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
VWF/FVIII products
Drug
Lead sponsor
Skane University Hospital
Other
Eligibility
Not listed
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 30, 2026, 6:19 AM EDT
Terminated Phase 3 Interventional Results available

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

NCT02967692
View directory record Official record
Conditions
Melanoma
Interventions
Spartalizumab, Placebo, Dabrafenib, Trametinib
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
12
States / cities
Encinitas, California • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 30, 2026, 6:19 AM EDT
Active, not recruiting Phase 2 Interventional

Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes

NCT04542148
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk, Diabetes, Gestational
Interventions
Sliding Scale Insulin, Up-Titration of Home Insulin, Continuous Insulin Infusion, Dexcom G6 Professional Continuous Glucose Monitor
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 50 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Portland, Oregon • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 30, 2026, 6:19 AM EDT
Terminated Phase 4 Interventional Results available

Steroids in Total Knee Arthroplasty

NCT02219581
View directory record Official record
Conditions
Postoperative Pain, Inflammation, Osteoarthritis
Interventions
Dexamethasone 10 mg, Dexamethasone 20 mg, Standard multimodal pain management regimen, Placebo
Drug
Lead sponsor
Thomas L Bradbury
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 30, 2026, 6:19 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of Pre-incisional Intravenous Ibuprofen to Reduce Postoperative Pain and Opioid Dependence After Posterior Cervical or Lumbar Instrumented Spine Surgery

NCT02276911
View directory record Official record
Conditions
Cervical Spondylosis, Lumbar Spondylosis
Interventions
Ibuprofen, normal saline
Drug · Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Not applicable Interventional

Study of Intensive, Home-Based Family Therapy to Improve Illness Management in Youth With Diabetes

NCT00372814
View directory record Official record
Conditions
Diabetes Mellitus, Insulin Dependent
Interventions
Intensive Home-Based Family Therapy, Supportive Telephone Calls
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
10 Years to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

NCT01400412
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Darunavir, Ritonavir, Tenofovir disoproxil fumarate, Emtricitabine, Placebo for Tenofovir disoproxil fumarate, Placebo for Maraviroc, Maraviroc
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

NCT01197755
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
fostamatinib, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
67
States / cities
Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 64 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Oct 30, 2026, 6:19 AM EDT
Not yet recruiting Not applicable Interventional

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

NCT07325214
View directory record Official record
Conditions
Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Interventions
IMD10, chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin]
Device · Drug
Lead sponsor
IMGT Co., Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • San Antonio, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

NCT00967616
View directory record Official record
Conditions
Colorectal Cancer, Neoplasms, Colorectal
Interventions
CS7017, irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Beverly Hills, California • Fullerton, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia

NCT04605484
View directory record Official record
Conditions
BK Virus Nephropathy, BK Virus Infection
Interventions
Posoleucel (formerly known as ALVR105) cells, Placebo (visually identical to Posoleucel)
Biological
Lead sponsor
AlloVir
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
33
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 30, 2026, 6:19 AM EDT
Active, not recruiting Phase 3 Interventional Results available

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

NCT01674140
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1454
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 888 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 6:19 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

NCT05992935
View directory record Official record
Conditions
Norovirus Acute Gastroenteritis
Interventions
mRNA-1403, mRNA-1405, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
14
States / cities
Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 6:19 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

NCT05590468
View directory record Official record
Conditions
Mitochondrial Myopathy
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement · Drug
Lead sponsor
Ralitza Gavrilova
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 30, 2026, 6:19 AM EDT